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Abstract
Background: The ATM protein is activated as a result of ionizing radiation, and genetic variants of the
ATM gene may therefore affect the level of radiation-induced damage. Individuals heterozygous for ATM
mutations have been reported to have an increased risk of malignancy, especially breast cancer.
Materials and methods: Norwegian breast cancer patients (272) treated with radiation (252 of which
were evaluated for radiation-induced adverse side effects), 95 Norwegian women with no known history
of cancer and 95 American breast cancer patients treated with radiation (44 of which developed ipsilateral
breast tumour recurrence, IBTR) were screened for sequence variations in all exons of the ATM gene as
well as known intronic variants by denaturating high performance liquid chromatography (dHPLC)
followed by sequencing to determine the nature of the variant.
Results and Conclusion: A total of 56 variants were identified in the three materials combined. A
borderline significant association with breast cancer risk was found for the 1229 T>C (Val>Ala)
substitution in exon 11 (P-value 0.055) between the Norwegian controls and breast cancer patients as well
as a borderline significant difference in haplotype distribution (P-value 0.06). Adverse side effects, such as:
development of costal fractures and telangiectasias, subcutaneous and lung fibrosis, pleural thickening and
atrophy were evaluated in the Norwegian patients. Significant associations were found for several of the
identified variants such as rs1800058 (Leu > Phe) where a decrease in minor allele frequency was found
with increasing level of adverse side effects for the clinical end-points pleural thickening and lung fibrosis,
thus giving a protective effect. Overall our results indicate a role for variation in the ATM gene both for
risk of developing breast cancer, and in radiation induced adverse side effects. No association could be
found between risk of developing ipsilateral breast tumour recurrence and any of the sequence variants
found in the American patient material.
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The ATM gene was localized to the chromosomal sub-
band 11q22-q23 by genetic linkage analysis in families
with members affected by ataxia telangiectasia (AT) in
1988. AT is an inherited recessive disorder associated with
neurological dysfunction, growth abnormalities, extreme
radio-sensitivity, immunological deficiency and increased
risk of malignancy [1-3]. The majority of AT- patients are
compound heterozygous with different mutations in each
allele of the gene, a large proportion of which are reported
to be truncating, giving rise to shorter versions of the pro-
tein where the C-terminal domain of the protein often is
deleted [4]. Individuals who are AT- heterozygous have
been reported to have intermediate radio-sensitivity and
an increased risk of malignancy, especially breast cancer
[3,5-10], possibly associated with genetic variance affect-
ing binding domains of the protein [11]. Estimates of car-
rier frequencies indicate that 0.5–1% of the population
are AT-carriers [8,12]. Studies in mice have shown that
ATM haploinsufficiency is followed by an increased sensi-
tivity to low doses of radiation, carcinogens and an
increased incidence of mammary tumours but not
increased radiation mutagenesis [13-15].
The ATM gene codes for a protein with 3056 amino acids
and a molecular weight of ~350 kDa which have been
found to exist both in monomeric (active) and dimeric
(inactive) state [16]. The protein contains several impor-
tant domains such as 1) the C-terminal protein kinase
domain (PI3K-domain), 2) the substrate binding domain
in the N-terminal of the protein necessary for activation of
p53 in response to DNA damage, 3)the FAT domain –
common for the PI3K-like family members FRAP, ATM
and TRAPP, 4) a proline rich region shown to bind c-Abl
and 5) an incomplete leucine zipper. For more detailed
description of the domains see the review by [17]. The
protein is primarily located in the nucleus but has also
been found in cytoplasmic vesicles called endosomes and
peroxisomes. In the peroxisomes ATM co-localized with
catalase which is involved in the detoxification of reactive
oxygen species [18,19].
The ATM protein is involved in the cell cycle control and
is a member of the phosphatidylinositol 3-kinase family,
implicated in the early response to DNA damaging agents,
such as ionizing radiation causing double strand breaks
(DSB) [16,20]. ATM possesses kinase activity and phos-
phorylates serine and threonine amino acids in several
important downstream cell cycle proteins such as p53,
BRCA1/2, CHK1/2 and c-Abl [18,20,21]. ATM deficient
cells are extremely sensitive to ionizing radiation (IR). It
has been shown that IR induces the instantaneous phos-
phorylation of the ATM protein at Ser-1981 leading to cat-
alytic activation by dimer dissociation rendering the
kinase domain accessible [22]. This activation continues
throughout the cell cycle although the protein level
remains constant [23]. Recent studies have identified two
additional serine residues, Ser-367 and Ser-1893 which
are phosphorylated as a response to DNA damage in vitro
and shown that site specific mutations of either one of the
three serine residues (367, 1893 and 1981) give rise to
proteins defective in ATM signalling in vivo [24]. Studies of
linkage disequilibrium (LD) patterns of the ATM gene
have revealed low recombination and extensive LD span-
ning the whole gene, in particular in the 3'- end of the
gene, with few haplotypes representing the majority of
chromosomes [25-27]. Studies of the associations of hap-
lotypes with breast cancer risk have revealed contradictory
results, some showing an increased risk associated with
particular haplotypes [27,28] while other found no such
association [29,30].
The aim of this study was to investigate the difference in
type and frequencies of ATM variants and haplotypes in
association with risk of breast cancer, as well as subcuta-
neous and cutaneous radiation induced adverse side
effects, development of costal fractures and pleural thick-
ening. In addition, we wanted to investigate whether an
association between genetic variation of the ATM gene
and the risk of developing local recurrence after radiation
treatment could be found.
Materials and methods
Norwegian controls
The control group for the Norwegian breast cancer cases
consisted of 95 post-menopausal women participating in
the National Mammography screening program, with no
history of breast cancer after two negative mammograms
[31]; age range at the time of blood collection was 55 – 72
years.
Norwegian breast cancer cases
The breast cancer cases used in this study has previously
been investigated for variations in the glutathione-S-trans-
ferase genes GSTP1, GSTM1 and GSTT1 and are also
described in detail in [32] as well as here: From 1975 to
1986 a total of 1496 patients diagnosed with breast cancer
and referred to the Norwegian Radium Hospital (NRH),
received their loco-regional radiation treatment with a
fractionation pattern of 4.3 Gray (Gy) x10 (2 treatments
per week for 5 weeks; total dose 43 Gy; treatment A). This
fractionation schedule was applied both as an adjuvant,
post-operative treatment and administered to women
who had RT after a loco-regional recurrence following
breast cancer surgery some years prior to referral to the
NRH. This RT schedule was expected to be more effective
and at the same time less resource-consuming than the
conventional fractionation pattern (2 Gy x25, 5 treat-
ments per week; total dose 50 Gy). The typical post-mas-
tectomy target fields covered the ipsilateral lymph nodePage 2 of 9
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the arteria mammaria interna. Depending on the extent of
the operation and/or the expected risk of local recurrence,
the thoracic wall was also irradiated [33]. Late adverse
effects are therefore expected in these anatomical regions,
manifested as telangiectasias of the skin, subcutaneous
fibrosis and atrophy, costal fractures, pleural thickening
and lung fibrosis. During the late 80's and early 90's evi-
dence accumulated for unjustifiably severe adverse side
effects following this type of RT. In 1996 it was decided
that all patients still alive (n = 289) should be systemati-
cally evaluated for radiation induced adverse effects
within the target field as a basis to estimate the level of
monetary compensation. A total of 245 patients took part
in this evaluation.
In parallel with treatment A, an alternative treatment reg-
imen was used (2.5 Gy x20, 4 treatments per week for 5
weeks; treatment B). This schedule still met the require-
ments related to limited RT capacity but was more in line
with the conventional fractionation pattern of 5 weekly
treatments of 2 Gy for 5 weeks. Treatment B was to be
applied mainly in patients with primarily inoperable
breast cancer, who could potentially be rendered operable
by RT. From 1975 to 1991, 617 women received treat-
ment B against the chest wall, with or without radiation to
the regional lymph nodes. Of these 617 women, 155 were
still alive in 1997. One-hundred-and-nineteen of these
patients agreed to be included in the evaluation study and
the same assessments of damage were performed as for
the treatment A group.
During the survey, the clinical examinations and overall
pain evaluation were performed by three dedicated oncol-
ogists. A physiotherapist assessed shoulder mobility and
arm oedema by comparison with the contra lateral arm
and also assessed the cutaneous and sub-cutaneous
adverse effects. A radiologist recorded pleural and lung
densities as seen on chest X-ray, in addition to the pres-
ence of costal fractures. Photographs of the irradiated
areas were taken and kept in the patient's medical record.
These photographs, together with the patient journals and
the original evaluation, were the source of this study's
scoring of cutaneous adverse effects, as assessed in 2004.
All adverse effects were scored as "none", "little", "some"
and "substantial", in part based on the CTC and Somalent
scoring system and in part on an ad hoc defined scoring
system based on the individual health professional's expe-
rience.
In the analysis of radiation-induced side effects we
excluded patients who, after their primary RT, had
repeated irradiations for loco-regional recurrence. As a
result there were a total of 253 patients included with 156
having received 4.3 Gy x10 (A) and 97 having received 2.5
Gy x20 (B). Of these, 5 women (1 given treatment A and
4 given treatment B) had inoperable tumours and
received the RT to shrink the tumour in order that they
could receive surgery. The remaining 248 women (155
receiving treatment A and 93 treatment B) received post-
operative RT [32].
American breast cancer cases
The patients included in this study were part of a larger
patient cohort containing a total of 1546 early stage breast
cancer patients treated at Yale New Haven Hospital
between 1973 and 1994 with lumpectomy followed by
radiotherapy (LRT). A total of 112 patients developed
ipsilateral breast tumour recurrence (IBTR), 52 of whom
consented to participate in this study (group 1). As a con-
trol group, 52 women with breast cancer treated with LRT
in the same period but not developing IBTR were collected
(group 2). The two groups were matched by age (± 5
years), year of treatment (± 5 years) and stage of the dis-
ease [34]. Leukocyte DNA was available for all 104 sam-
ples but mutation screening of the ATM gene was only
performed for 44 of the patients experiencing IBCT and 51
of the matched controls. This was done to fit into a 96 well
format analyses scheme, excluding the samples with the
poorest DNA quality and lowest DNA concentration.
Consent form and ethical committee
All samples were collected after proper informed consent
was obtained and the project was approved by the
regional ethical committee.
DNA isolation
Blood samples were collected in EDTA tubes and frozen
until time of leukocyte DNA isolation using chloroform/
phenol extraction followed by ethanol precipitation using
the Applied Biosystems 340A Nucleic Acid Extractor and
according to standard procedures.
Genotyping Method
All individual exons of the ATM gene and some flanking
intronic regions with known variants were screened for
variants by denaturating high performance liquid chro-
matography (dHPLC). A thorough description of the
method can be found in [35]. Briefly, individual exons
and the included intronic regions were amplified by PCR
and screened for variations performing heteroduplex
analysis and separation on the Transgenomic® Wave Sys-
tem. Heteroduplexes were identified by abnormal band
pattern appearing on the chromatograms and samples
with possible variations were subjected to direct sequenc-
ing of a newly amplified PCR fragment to determine the
nature of the variant. Samples with a dHPLC band pattern
deviating from the reference sequence, but without evi-
dence for a heteroduplex were also submitted to direct
sequencing in order to capture any homozygote variant.Page 3 of 9
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by two investigators. Sequence information on all PCR
primers as well as the PCR and dHPLC conditions can be
found in [35].
Statistical Methods
To test the statistical significance of the difference in gen-
otype distribution between two groups Chi-square tests
were performed using SPSS 13.0. All p-values of single
marker associations are two sided and not corrected for
multiple testing. The haplotypes were estimated using
Phase v.2.1.1 and the significance of the difference in hap-
lotype distribution between two or more groups were
obtained using the case-control permutation analysis
implemented in Phase that tests whether the estimated
haplotypes in the case and control groups are a random
sample from a single set of haplotype frequencies or if
cases are more similar to other cases than to controls
[36,37].
In silico protein analysis
The online protein prediction tool PolyPhen [38] was uti-
lized to assess the possible functional effect of a sequence
variation in the coding regions of the ATM gene resulting
in an amino-acid substitution in the protein sequence.
The online tool scores the effect of a non-synonymous
variation as benign, possibly damaging or probably dam-
aging.
Results
Screening of the exonic regions of the ATM gene, as well
as known intronic variants, in three materials: Norwegian
controls (material 1), Norwegian breast cancer cases
(material 2) and American breast cancer cases, with or
without ipsilateral breast tumour recurrence (material 3),
identified a total of 56 variations; 55,4 % transitions (n =
31), 32,1 % transversions (n = 18) and 12,5 % insertions/
deletions (n = 7), [see Additional file 1]. Of these, 10 were
intronic and 36 exonic, the latter sub-grouped into: 3
truncating, 10 synonymous and 23 non-synonymous.
Estimations of Hardy-Weinberg equilibrium were per-
formed for the variants detected in the Norwegian con-
trols, none of the variants deviated from Hardy-Weinberg
equilibrium (data not shown). Nine of the 56 identified
variants were found in all three materials, an additional 7
were common for the Norwegian materials (material 1
and material 2) and three for the breast cancer materials
(material 2 and material 3). The variations were distrib-
uted throughout the gene, with the highest number of var-
iants found in close proximity to or within exon 39 (5
variants), exon 31 (4 variants) and exon 8,15,32,52 and
60 (3 variants identified in each). The location of the
identified variants along the gene as well as the exons rel-
ative to the domains of the protein described by [17], such
as the PI3K domain, substrate binding domains and ATP-
binding domains, is illustrated in Figure 1.
Single marker associations
Risk for developing breast cancer
The association between any variant in the ATM gene and
risk of breast cancer was computed by comparing the 95
cancer free women and the 272 breast cancer patients
from Norway. A total of 43 variants were identified in the
two materials combined [see Additional file 1]. The vari-
ant in exon 11 (variant nr. 10, Additional file 1), where a
T to C substitution causes an amino-acid change from
valine to alanine in the Leucine zipper domain, was found
borderline significantly associated with risk of develop-
ment of breast cancer (P = 0.055), with a lower frequency
of the minor allele in breast cancer patients, suggesting a
protective effect for of this variant (Table 1).
Association of variance in ATM with adverse side effects of 
radiotherapy
The impact of variation in the ATM gene on the level of
radiation induced side effects: costal fractures, subcutane-
ous and lung fibrosis, pleural thickening, development of
telangiectasias and atrophy, was studied in the Norwegian
breast cancer patients. Twenty individuals were excluded
from this analysis as a consequence of receiving multiple
radiotherapy treatments to the same area, thus making it
difficult to evaluate radiation induced damage from one
specific treatment. The remaining 252 patients were first
analyzed in combination (Table 2, a) and then divided
according to treatment regimen and analyzed separately
(Table 2b and 2c). A total of 154 and 94 patients received
treatment A (4.3 Gy *10) and B (2.5 Gy *20) respectively.
Several of the detected ATM variants were rare [see Addi-
tional file 1] and association analyses with level of radia-
tion induced side effects were performed only for those
with minor allele frequency > 1%. Even at this low fre-
quency, several of the SNPs were found associated to one
or more of the studied end-points: costal fractures, pleural
thickening, subcutaneous and lung fibrosis, development
of telangiectasias and atrophy both when all cases were
analyzed in combination and when the cases were divided
into two groups according to received treatment regimen
(Table 2a,b and 2c). The change of a G with an A in exon
39 (rs1801516) was found significantly associated with
the development of telangiectasias when all cases were
analyzed combined (P-value 0.042), and the association
became even more significant when only the patients
receiving treatment A were analyzed (P-value 0.027). The
association is caused by a decreasing frequency of the
minor allele with increasing level of radiation induced
side effects indicating a protective effect for the A allele.
The C to T transition in exon 31 (rs1800058) altering the
aminoacid in position 4258 from Leu to Phe was found
associated with pleural thickening and lung fibrosis in allPage 4 of 9
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points) as well as only in the patients receiving treatment
B (P-value 0.001 and 0.002 respectively). Also in this
patient group a borderline significant association was
observed between this variant and development of costal
fractures (P-value 0.055). The impact of this association
and other listed in Table 2 have to be interpreted with cau-
tion since the number of identified variant alleles is very
low and the number of cases limited.
Risk for ipsilateral breast tumour recurrence
None of the variants identified in the American breast
cancer patients were found associated with risk of devel-
oping ipsilateral breast tumour recurrence (IBTR) at the
single marker level although some differences in minor
allele frequencies were seen (data not shown).
Association of heterozygosity of the ATM gene with adverse side 
effects of radiotherapy and risk for ipsilateral breast tumour 
recurrence (IBTR)
To assess the influence of variation in the ATM gene focus-
ing on variants 1) affecting a splice site, 2) leading to a
truncated version of the protein or 3) scored as probably
or possibly damaging in PolyPhen, all patients with pres-
ence of one or more such sequence variation in the ATM
gene where combined into one group. The level of adverse
side effects in the Norwegian breast cancer patients or risk
of IBTR in the American breast cancer cases were then
Schematic illustration of the ATM geneFigure 1
Schematic illustration of the ATM gene. The distribution of the variations detected in the studied materials along the gene is 
shown in the upper panel with exonic variants indicated on top of the gene and intronic below the gene, illustrated by colored 
triangles (pink for Norwegian controls, blue for Norwegian breast cancer patients and green for American breast cancer 
patients, numbers above/below is consistent with numbering used in Additional file 1). Below is given an illustration of the pro-
tein with important areas such as substrate binding domains, Leucine zipper, ATP-binding domains, FAT domain and PI3K 
domain [17] together with exonic information. (The size of the exons and the distance between them are not indicative of the 
sizes/distances in the gene/protein).
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Table 1: 
Exon/Variant Genotype Cases Controls P-value
Exon 11
1229 T>C TT 270 92 0.055
Val > Ala TC 1 3
Variant associated at the single marker level with development of 
breast cancer in the Norwegian breast cancer patientsPage 5 of 9
(page number not for citation purposes)
Radiation Oncology 2007, 2:25 http://www.ro-journal.com/content/2/1/25compared between the group of patients with and the
group of patients without any detected variation in the
ATM gene fulfilling these criteria. No significant associa-
tion could be found between the presence of such
sequence variations in the ATM gene for any of the
assessed end-points in the Norwegian breast cancer
patients or the American breast cancer patients (data not
shown).
Haplotype associations
Risk for developing breast cancer
A trend for difference in frequency distribution of the hap-
lotypes of the ATM gene was found between cases and
controls when including all identified variants, (P-value
0.06) but it did not reach statistical significance. Phased
estimations based on both cases and controls gave 51 hap-
lotypes of which 12 were found in both cases and con-
trols, 9 only in the controls and 30 only in the cases [see
Additional file 2]. In addition, one haplotype was only
found when analyzing the controls and another three
only when analyzing the cases separately. The ten most
frequent haplotypes were in common for both materials,
and the top three accounted for 73.6%, 79.9% and 71.3%
of the total number of represented chromosomes when
analyzing cases and controls combined, only controls and
only cases respectively. Calculating the difference in fre-
quency distribution of the phased haplotypes, including
only the variants with a minor allele frequency ≥ 1% in
cases or controls, gave a P-value = 0.23. The low frequent
variants tend to reside on different haplotypes.
Association with adverse side effects of radiotherapy
No significant association was found between haplotype
distribution and the radiation induced adverse side effects
studied here, whether the analyses were performed for all
cases combined or split by treatment regimen (data not
shown).
Risk for ipsilateral breast tumour recurrence
No significant difference in haplotype distribution was
found in the American breast cancer cases with relation to
risk of developing ipsilateral breast tumour recurrence. In
both groups the three most frequent estimated haplotypes
accounted for more than 78% of the analyzed chromo-
somes (data not shown).
Discussion and conclusion
It has been reported that the coding regions of the ATM
gene has a reduced nucleotide diversity in human and
chimpanzee as compared to other genes such as ABCB1,
BRCA1/2, PTGS2 and XRCC1, in particular the last 2650
bp of gene containing among other the PI3K domain [26].
Our results clearly illustrated this by the fact that only
11% of the total variation is found within this area. In
addition, we see no variation in exon 6, which contains
Table 2: 
Exon/Variant Genotype Level of adverse effects P-value
0 1 2 3
a)
Pleural thickening
Exon 20 GG 136 82 23 1 0.001
IVS20+28delG GA 4 2 0 1
Exon 31, rs1800058 CC 135 82 23 1 > 0.001
4258 C>T CT 5 1 0 1
Leu > Phe
Exon 41, rs3092910
5793 T>C TT 136 82 23 1 0.001
Ala > Ala TC 4 2 0 1
Lung fibrosis
Exon 31, rs1800058 CC 66 156 18 1 > 0.001
4258 C>T CT 3 3 0 1
Leu > Phe
Development of telangiectasias
Exon 39, rs1801516 GG 35 33 41 70 0.042
5557 G>A GA 11 14 10 20
Asp > Asn AA 4 1 0 0
Atrophy
Exon 31, rs1800058
4258 C>T CC 35 57 74 65 0.02
Leu > Phe CT 4 1 0 2
b)
Pleural thickening
Exon 20 GG 69 61 19 0 > 0.001
IVS20+28delG GA 2 2 0 1
Exon 41, rs3092910 TT 69 61 19 0 > 0.001
5793 T>C TC 2 2 0 1
Ala > Ala
Lung fibrosis
Exon 32, rs1800889 CC 11 111 13 0 0.009
4578 C>T CT 4 11 2 1
Pro > Pro
Development of telangiectasias
Exon 39, rs1801516 GG 14 21 28 47 0.027
5557 G>A GA 4 9 9 15
Asp > Asn AA 3 1 0 0
c)
Costal fractures
Exon 9, rs3218674 CC 75 12 1 0 0.043
735 C>T CT 6 0 1 0
Val > Val
Pleural thickening
Exon 31, rs1800058 CC 64 20 4 0 0.001
4258 C>T CT 5 0 0 1
Leu > Phe
Lung fibrosis
Exon 31, rs1800058 CC 51 35 2 0 0.002
4258 C>T CT 3 2 0 1
Leu > Phe
Subcutaneous fibrosis
Exon 32, rs1800889 CC 32 25 16 5 0.022
4578 C>T CT 6 1 0 3
Pro > Pro
Associations of genetic variance in the ATM gene with radiation induced 
side effects in the Norwegian breast cancer patients: for all patients 
combined (a), treatment A (4.3 Gy *10, b) and treatment B (2.5 Gy *25, c) 
(organized by adverse effect, level of adverse effect is divided into four 
groups: none (0), little (1), some (2) and substantial (3)). (The P-values are 
not adjusted for multiple testing)Page 6 of 9
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tion. In a recent study of French AT-families [11] no differ-
ence in risk of breast cancer was detected between
heterozygous truncating mutations and missense/in-
frame deletions. Three high risk groups of truncating
mutations were identified each of which were associated
to a known binding domain of the ATM protein. Studying
the association between sequence variations in the ATM
gene and risk of breast cancer in seven family branches
[39] found no association with mutations that truncate
the ATM protein in these domains. This is in line with our
results where the variant in exon 11 found associated with
breast cancer risk is also not located in any of these
domains. In a recently reported in vitro study the
rs1800056 (Phe > Leu) and the rs1800057 (Pro > Arg) var-
iants were found to modify chromosomal radiosensitivity
in lymphoblastoid cell lines from AT-patients, AT-hetero-
zygous and normal individuals [40]. These two variants
were not associated with radiation induced adverse side
effects in our study, but the rs1800058 (Leu > Phe), not
found associated by [40] was linked to several of the clin-
ical end-points analyzed here. [28] identified an associa-
tion between the variant rs1801516 with radiosensistivity
in French breast cancer patients caused by an overrepre-
sentation of the A allele in the breast cancer cases who
where adverse radiotherapy responders. This result is sup-
ported by the study of [41] where a trend towards
increased radiosensitivity of human fibroblast where
found with the presence of the variant genotype. This is in
contrast with our results indicating a protective effect of
the A allele. The contradictory between our study and that
of [28] may be a consequence of the different ethnicity of
the populations or possibly a result of the limited study
population in the French study with only 70 radiosensitiv-
ity breast cancer cases included.
In accordance with recent studies we found that a small
number of haplotypes represents the majority of the ana-
lyzed chromosomes [25,26], both in cases and controls.
From a study of Korean breast cancer patients [42]
reported a significantly different frequency distribution of
the estimated haplotypes between cases and controls
when analyzing five ATM SNPs with a minor allele fre-
quency of more than 10%. None of the same variants
were detected in our study as a consequence of both exper-
imental design and the different populations studied but
a trend indicating the same was found when analyzing
our results although it did not reach statistical signifi-
cance. Our data suggest that the low frequent variants are
in part causing this difference.
Overall our results indicate a role for variation in the ATM
gene both for risk of developing breast cancer, and in radi-
ation induced adverse side effects, although the findings
need to be confirmed in larger studies.
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TRAPP Transformation/transcription domain-associated
protein, new gene symbol: TRRAP
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